Lori La Bey talks with Frank Amato, CEO and President, SYNAPS Dx, which offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. DISCERN is commercialized under the Clinical Laboratory Improvement Amendments (CLIA) and is reimbursed by Medicare.

Learn:

1. What is SYNAPS Dx, working on?
2. What is Discern.
3. How often should a person who is diagnosed with dementia, be reassessed?
4. If Doctors know what support is available to families living with dementia.
5. What is the fingers Study?
6. How we can get services, products, and tools to doctors to pass along to families?
7. Is the Discern test covered by insurance?

 

Listen and Subscribe to Alzheimer’s Speaks on Apple Podcast

https://podcasts.apple.com/us/podcast/alzheimers-speaks/id986940432

Listen and Subscribe to Alzheimer’s Speaks on Spotify

https://open.spotify.com/show/255okRnEgfCUqXq1NWcrT3

 

Contact SYNAPS Dx

Website  https://www.synapsdx.com/

Website https://discerntest.com/

Frank LinkedIn  www.linkedin.com/in/frank-amato-3b2a162/

SYNAPS Dx LinkedIn  www.linkedin.com/company/synapsdx/

SYNAPS Dx Facebook  www.facebook.com/discerntest

SYNAPS Dx Twitter (X)  @getdiscern

SYNAPS Dx Instagram  @getdiscern

 

Contact Lori La Bey with questions or branding needs at https://www.alzheimersspeaks.com/

Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world one episode at a time by raising all voices and delivering sound news, not just sound bites since 2011.

 

Alzheimer's Speaks is part of the Senior Resource Podcast Network.

Support this Show: https://alzheimersspeaks.com/donate-now/

See omnystudio.com/listener for privacy information.